La proteína priónica dimérica soluble se une a PrP (Sc) in vivo y antagoniza la enfermedad priónica

Philipp Meier1, Nicolas Genoud, Marco Prinz

  • 1Institute of Neuropathology, Schmelzbergstrasse, University Hospital of Zürich, Zürich, Switzerland.

Cell
|April 8, 2003
PubMed
Resumen

Los derivados de proteínas priónicas solubles, como PrP-Fc2, pueden bloquear la conversión de la proteína priónica celular normal (PrPC) en formas infecciosas de PrPC, inhibiendo así la replicación de priones y las enfermedades.

Videos de Conceptos Relacionados

Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
748
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
13.0K
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
8.7K